Skip to main content
SpringerLink
Log in

Therapie der Stoffwechselstörungen bei Sepsis: Pharmakologische Beeinflussung

  • Conference paper
Metabolismus

Part of the book series: Intensivmedizinisches Seminar ((INTENSIVM.SEM.,volume 7))

  • 39 Accesses

Zusammenfassung

„Metabolic care of the critically ill“ ist der Titel eines von D. Wilmore geschriebenen Buches, das 1975 erschien [1]. In diesem Buch beschreibt Wilmore die Stoffwechselveränderungen und die daraus abzuleitenden therapeutischen Maßnahmen beim Intensivpatienten. Als primäre therapeutische Stoffwechseltherapie wird in diesem Buch vor allem eine gezielte parenterale Ernährung angesehen. Das Spektrum der Stoffwechseltherapie hat sich in den letzten Jahren wesentlich erweitert, und wir befinden uns zur Zeit diesbezüglich in einer faszinierenden Phase von neuen Erkenntnissen, wobei vor allem die Entdeckung der Zytokine/Wachstumsfaktoren und das Verstehen der Kreislaufregulation über das einfache Molekül Stickoxid (NO) zu vermerken sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Wilmore DW (1977) The metabolic management of the criticall ill. Plenum, New York

    Google Scholar 

  2. Wilmore DW (1991) Catabolic illness. Strategies for enhancing recovery. N Engl J Med 325: 695–702

    Article  PubMed  CAS  Google Scholar 

  3. Newsholm EA, Newsholme P, Curi R, Challoner E, Ardawi MSM (1988) The role for muscle in the immune system; its importance in surgery, trauma, sepsis and burns. Nutrition 4: 261–268

    Google Scholar 

  4. Roth E, Funovics J, Mühlbacher F, Schemper M, Mauritz W, Sporn P, Fritsch A (1981) Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr 1: 25–41

    Article  Google Scholar 

  5. Häussinger D, Lang F (1991) Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochim Biophys Acta 1071: 331–350

    PubMed  Google Scholar 

  6. Häussinger D, Roth E, Lang F, Gerok W (1993) Cellular hydration state: an important determinant of protein catabolism in health an disease. Lancet 341: 1330–1332

    Article  PubMed  Google Scholar 

  7. Roth E, Karner J, Ollenschläger G (1990) Glutamin an anabolic effector? J Parent Ent Nutr 14: 130 S-136 S

    Article  Google Scholar 

  8. Roth E, Karner J, Roth-Merten A, Winkler S, Valentini L, Schaupp K (1991) Effect of a-ketoglutarate infusions on organ balances of glutamine and glutamate in anaesthetized dogs in the catabolic state. Clin Sci 80: 625–631

    PubMed  CAS  Google Scholar 

  9. Lowe DK, Benfell K, Smith RJ, Jacobs DO, Murawsji B, Ziegler TR, Wilmore DW (1990) Safety of glutamine-enriched parenteral nutrient solutions in humans. Am J Clin Nutr 52: 1101–1106

    PubMed  CAS  Google Scholar 

  10. Karner J, Roth E, Ollenschläger G, Fürst P, Simmel A, Karner J (1989) Glutamine-containing dipeptides as infusion substrates in the septic state. Surgery 106: 893–900

    PubMed  CAS  Google Scholar 

  11. Roth E, Winkler S, Hölzenbein T, Valentini L, Karner J (1992) High load of alanylglutamine in two patients with acute pancreatitis. Clin Nutr 11: 82 S

    Article  Google Scholar 

  12. Lowry SF (1993) Anticytokine therapies in sepsis. New Horizons 1: 120–126

    PubMed  CAS  Google Scholar 

  13. Werdan K (1993) Neue Aspekte der Sepsis-Behandlung — Additive Therapiemaßnahmen mit Antikörpern und Antagonisten gegen Bakterientoxine and Sepsismediatoren sowie mit Immunglobulinen. Intensivmedizin 30: 201–217

    Google Scholar 

  14. Ziegler EJ, Fisher CF, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berrger HJ, Knatterud GL, LoBuglio AF, Smith CR, HA-1A Sepsis Study group (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin — A randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429–436

    Article  PubMed  CAS  Google Scholar 

  15. Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, XOMA Sepsis Study Group (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097–1102

    Google Scholar 

  16. Engelmann H, Novick D, Wallach D (1990) Two tumor necrosis factor-binding proteins purified from human urine. J Biol Chem 265: 1531–1536

    PubMed  CAS  Google Scholar 

  17. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664

    Article  PubMed  CAS  Google Scholar 

  18. Epstein FH (1993) The role of interleukin-1 in disease. N Engl J Med 328: 106–113

    Article  Google Scholar 

  19. Gershenwald JE, Fong YM, Fahey TJ III, et al (1990) Interleukin i receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 87: 4966–70

    Article  PubMed  CAS  Google Scholar 

  20. Fisher CJ, Slotman GJ, Opal S (1991) Interleukine-1 receptor antagonist (IL-lra) reduces mortality in patients with sepsis syndrome. Annual Meeting of the American College of Chest Physicans, San Francisco (Abstract)

    Google Scholar 

  21. Fisher C, Dhainaut JF, Pribble J, Knaus W, IL-lra Phase III Sepsis Syndrome Study Group (1993) Interleukine-1 receptor antagonist: pharmacological and clinical review. International Conference on Sepsis in the ICU: A Masterclass Symposium, London (Abstract )

    Google Scholar 

  22. Liljedahl SO, Gemzell CA, Plantin LO, Birke G (1961) Effect of human growth hormone in patients with severe burns. Acta Chir Scand 122: 1–14

    PubMed  CAS  Google Scholar 

  23. Ziegler TR, Young LS, Manson JM, Wilmore DW (1988) Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg 208: 6–16

    Article  PubMed  CAS  Google Scholar 

  24. Jiang ZM, He GZ, Zhang SY, Wilmore DW (1989) Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Surgery 210: 513–524

    CAS  Google Scholar 

  25. Gottardis M, Benzer A, Koller W, Luger TJ, Puhringer F, Hackl J (1991) Improvement of septic syndrome after administration of recombinant human growth hormone (rhGH)? J Trauma 31: 81–86

    Article  PubMed  CAS  Google Scholar 

  26. Belcher HJCR, Mercer D, Judkins KC, et al (1991) Biosynthetic human growth hormone in burned patients: a pilot study. Burns 15: 99–107

    Article  Google Scholar 

  27. Roth E, Valentini L, Semsroth M, Hölzenbein T, Plattner H, Winkler S, Blum WF, Ranke MB, Hammerle A, Karner J (1992) No nitrogen sparing effect of recombinant human growth hormone in patients with multiple trauma. J Endocrinol Invest 15: 97 S

    Google Scholar 

  28. Voerman HJ, Strack van Schijndel RJM, Groeneveld ABJ, DeBoer H, Nauta JP, van derVeen EA, Thijs LG (1992) Effects of recombinant human growth hormone in patients with severe sepsis. Surgery 216: 648–655

    CAS  Google Scholar 

  29. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C (1991) Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor I. Clin Endocrinol 35: 47–54

    Article  CAS  Google Scholar 

  30. Miell JP, Taylor AM, Jones J, et al (1992) Administration of human recombinant insulin-like growth factor I to patients following major gastrointestinal surgery. Clin Endocrinol 37: 542–551

    Article  CAS  Google Scholar 

  31. Mauras N, Horber FF, Haymond MW (1992) Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin End Met 75: 1192–1197

    Article  CAS  Google Scholar 

  32. Roth E, Valentini L, Hölzenbein T, Winkler S, Sautner T, Hörtnagl H, Karner J (1993) Acute effects of insulin-like growth factor I on interorgan amino acid flux in protein-catabolic dogs. Biochem J 296: 765–769

    PubMed  CAS  Google Scholar 

  33. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109–141

    PubMed  CAS  Google Scholar 

  34. Palmer RM (1993) The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis. Arch Surg 128: 396–401

    Article  PubMed  CAS  Google Scholar 

  35. Lorente JA, Landin L, dePablo P, Renes E, Liste D (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21: 1287–1295

    Article  PubMed  CAS  Google Scholar 

  36. Roth E, Steininger R, Winkler S, Längle F, Grünberger T, Függer R, Mühlbacher F (1994) L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft. Influence on nitric oxide metabolism. Transplantation 57: 1–6

    Article  Google Scholar 

  37. Boekstegers P, Weidenhöfer ST, Pilz G, Werdan K (1991) Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: comparison to limited infection and cardiogenic shock. Infection 19: 317–323

    Article  PubMed  CAS  Google Scholar 

  38. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB (1991) Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 214: 621–626

    Article  PubMed  CAS  Google Scholar 

  39. Curran RD, Billiar TR, Stuehr DJ, Ochoa JB, Harbrecht BG, Flint SG, Simmons RL (1990) Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg 212: 462–471

    Article  PubMed  CAS  Google Scholar 

  40. Geng Y-J, Hansson GK, Holme E (1992) Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 71: 1268–1276

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chirurgisches Stoffwechselforschungslabor, Klinik für Chirurgie, Universität Wien, Österreich

    Prof. Dr. E. Roth

Authors
  1. Prof. Dr. E. Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Steyr, Österreich

    Gunther Kleinberger

  2. Wien, Österreich

    Kurt Lenz , Bruno Schneeweiß  & Werner Waldhäusl ,  & 

  3. Basel, Schweiz

    Rudolf Ritz

  4. Hildesheim, Deutschland

    Hans-Peter Schuster

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag/Wien

About this paper

Cite this paper

Roth, E. (1994). Therapie der Stoffwechselstörungen bei Sepsis: Pharmakologische Beeinflussung. In: Kleinberger, G., Lenz, K., Ritz, R., Schneeweiß, B., Schuster, HP., Waldhäusl, W. (eds) Metabolismus. Intensivmedizinisches Seminar, vol 7. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9342-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9342-6_10

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82538-9

  • Online ISBN: 978-3-7091-9342-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation